Early-stage diffuse large B cell lymphoma of the head and neck: clinico-biological characterization and 18 year follow-up of 488 patients (IELSG 23 study)
Artículo
Publication date
2014Metadata
Show full item record
Cómo citar
Mian, M.
Cómo citar
Early-stage diffuse large B cell lymphoma of the head and neck: clinico-biological characterization and 18 year follow-up of 488 patients (IELSG 23 study)
Author
- Mian, M.;
- Capello, D.;
- Ventre, M. B.;
- Grazio, D.;
- Svaldi, M.;
- Rossi, A.;
- Tsang, R.;
- Gospodarowicz, M. K.;
- Oldani, E.;
- Federico, M.;
- Luminari, S.;
- Marcheselli, L.;
- Pogliani, E. M.;
- Rossini, F.;
- Cabrera Contreras, María Elena;
- Martelli, M.;
- Gutiérrez García, G.;
- Busetto, M.;
- Visco, C.;
- Fiegl, M.;
- Rossi, D.;
- Gaidano, G.;
- Cavalli, F.;
- Zucca, E.;
- Rambaldi, A.;
- Cortelazzo, S.;
Abstract
It is known that extranodal head and neck diffuse
large B cell lymphomas (eHN-DLBCL) can affect various
anatomical structures what is not well-known, however, is
whether they differ in terms of clinical presentation and outcome.
Clinical data of the multi-institutional series, the largest
of its kind as yet, has been analysed with the aim of answering
these open questions and providing long-term follow-up information.
Data from 488 patients affected by stage I/II eHNDLBCL
was collected: 300 of the Waldeyer’s Ring (WR), 38
of the parotid and salivary glands (PSG), 48 of the thyroid gland
(TG), 53 of the nasal cavity and paranasal sinuses (NPS), 24 of
the palate and oral cavity (POC) and 25 with more than one involved site. Different eHN-DLBCL arising have distinct
characteristics at presentation. The intermediate high riskmodified
IPI was 67 % in TG, 44 % in WR, 38 % in PSG
and POC and 20 % in MS. The worst 5-year survival rate had
TG-DLBCL (61%) due to the 61%of patients with amIPI >1.
The addition of radiotherapy (cRT) to remitters did not translate
into a survival advantage (5-year disease-free survival of
67 % in the cRT group vs. 70 % in the other). Three of four
central nervous system recurrences occurred in NPS-DLBCL.
Survival of HN-DLBCL was inferior to nodal DLBCL. This
study showed that eHN-DLBCL remitters have an inferior
survival when compared to nodal DLBCL, and that the addition
of cRT does not provide a survival advantage. Since the
standard of care nowadays is chemo-immunotherapy, survival
of these patients might have been improved.
General note
Artículo de publicación ISI
Identifier
URI: https://repositorio.uchile.cl/handle/2250/129463
DOI: DOI: 10.1007/s00277-013-1856-4
Quote Item
Ann Hematol (2014) 93:221–231
Collections